Azithromycin/hydroxychloroquine/steroidsLack of efficacy and off-label use in an unapproved indication

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2014卷 / 1期

关键词：

D O I：

10.1007/s40278-024-61532-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：104 / 104

相关论文

共 50 条

[1] Abatacept/cyclophosphamideLack of efficacy and off-label use in unapproved indication
Reactions Weekly, 2024, 2006 (1) : 13 - 13
[2] Baricitinib/dexamethasone/remdesivirLack of efficacy and off-label use in unapproved indication
Reactions Weekly, 2024, 1999 (1) : 81 - 81
[3] MethylprednisoloneLack of efficacy and off-label use in unapproved indication: case report
Reactions Weekly, 2024, 2021 (1) : 303 - 303
[4] Antipsoriatics/dupilumabLack of efficacy and off-label use in unapproved indication: case report
Reactions Weekly, 2023, 1961 (1) : 66 - 66
[5] DexamethasoneLack of efficacy following off-label use (in unapproved indication): case report
Reactions Weekly, 2024, 2025 (1) : 160 - 160
[6] Multiple drugsLack of efficacy and off-label use in unapproved indication: case report
Reactions Weekly, 2024, 2028 (1) : 336 - 336
[7] Azacitidine/VenetoclaxLack of efficacy and off-label therapy in unapproved indication
Reactions Weekly, 2023, 1986 (1) : 83 - 83
[8] EltrombopagLack of efficacy following off-label use in unapproved indication: 3 case reports
Reactions Weekly, 2025, 2046 (1) : 149 - 149
[9] Multiple drugsLack of efficacy and off-label use (in unapproved indication): 4 case reports
Reactions Weekly, 2023, 1966 (1) : 245 - 245
[10] Anti-inflammatoriesLack of efficacy, off-label use in unapproved indication and drug ineffective for unapproved indication: 5 case reports
Reactions Weekly, 2023, 1960 (1) : 36 - 36

← 1 2 3 4 5 →